CDKN2A and meningioma: A recent study published by the same research group demonstrated that using the 2021 WHO grade for the integrated score does not produce any substantial changes; therefore, according to this result, there is no need for additional testing for pTERT and/or homozygous losses of CDKN2A/B when defining the integrated score in risk prediction for meningioma patients [37].